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Introduction {#sec001}
============

Infectious laryngotracheitis (ILT) is an acute and highly contagious respiratory disease of chickens caused by the *Gallid herpesvirus* 1 (GaHV-1), also called infectious laryngotracheitis virus (ILTV) \[[@pone.0149529.ref001]\]. ILTV is classified as a member of the genus *Iltovirus*, subfamily *Alphaherpesvirinae*, family *Herpesviridae* \[[@pone.0149529.ref002]\]. The virus has a linear dsDNA genome of about 150 kb composed of a unique long (UL), a unique short (US) region, and inverted internal (IR) and terminal (TR) repeats. The genome encodes 80 predicted viral protein open reading frames (ORFs): 65 ORFs are located within the UL region and nine within the US region, while the inverted repeats contain only three genes (ICP4, US10, and sORF4/3) \[[@pone.0149529.ref003]\].

Since its early appearance, several manifestations of ILT have been described associated with mortality and/or decreased egg production and causing significant economic losses to the poultry industry \[[@pone.0149529.ref001]\]. In commercial chicken flocks the disease is primarily controlled by vaccination and several types of vaccines have been produced, including killed, live attenuated and the recent recombinant vaccines \[[@pone.0149529.ref004]\]. Live attenuated vaccines are produced by sequential passages in tissue cultures (tissue culture origin, TCO) or embryonated eggs (chicken embryo origin, CEO) \[[@pone.0149529.ref001]\]. However, these vaccines may retain residual virulence and revert to virulence after bird-to-bird passage resulting in disease in unprotected flocks \[[@pone.0149529.ref005], [@pone.0149529.ref006]\].

In the last decade, several molecular studies \[[@pone.0149529.ref007]--[@pone.0149529.ref018]\] have provided evidence that strains identical or closely related to CEO vaccines have been involved in ILT outbreaks worldwide. These observations have been recently strengthened by full genome sequence-based analyses, which demonstrated that some reverted live attenuated vaccines were the main source of ILT outbreaks \[[@pone.0149529.ref004], [@pone.0149529.ref006]\]. A total of 22 full DNA sequences of wild-type and vaccine strains from Australia \[[@pone.0149529.ref003], [@pone.0149529.ref015], [@pone.0149529.ref019], [@pone.0149529.ref020]\], USA \[[@pone.0149529.ref016], [@pone.0149529.ref021], [@pone.0149529.ref022]\], and China \[[@pone.0149529.ref023]\] have been recently determined and are currently available at the NCBI GenBank nucleotide database. Except for the European Serva vaccine strain sequenced by an Australian research group \[[@pone.0149529.ref003]\], no full genome sequences of European ILTV strains have been determined to date.

In Italy, epidemics of ILT have followed a cyclical pattern. One severe epidemic caused by virulent ILTV strains occurred during the '80s \[[@pone.0149529.ref024]\]. Afterward, vaccination was introduced to control the disease, and ILTV disappeared to re-emerge in 2007 when a second epidemic of mild respiratory disease started to affect broiler flocks \[[@pone.0149529.ref025]\]. Currently, four ILT CEO vaccines are licensed in Italy and only long-living birds (*i*.*e*. breeders and layers) are routinely vaccinated. In a previous study \[[@pone.0149529.ref025]\], PCR-RFLP and sequencing analysis of six genes (*i*.*e*. gE, gG, TK, ICP4, ICP18.5, and ORFB-TK) suggested that some ILTV isolates involved in recent ILT outbreaks in Italy might have been originated from CEO vaccines.

In this study, the full genome sequences of five Italian ILTV strains were determined using the high throughput 454 Life Sciences sequencing technology. One field isolate from a historical case of ILT (1980), two field isolates from recent cases of ILT (2007 and 2011) and two commercially available CEO vaccine viruses (Nobilis Laringovac^®^, MSD Animal Health and Poulvac ILT^®^, Zoetis) were sequenced for analysing and comparing the genomes. The ultimate goal of this study was to identify genetic variation among wild-type isolates from different years and two distinct Italian epidemics of ILT, as well as between wild-type and vaccine strains.

Materials and Methods {#sec002}
=====================

Virus {#sec003}
-----

Five ILTV strains were sequenced: one field isolate from a historical case of ILT (1980 ILTV field isolate, 4787/80), two field isolates from recent cases of ILT (2007 ILTV field isolate, 193435/07, and 2011 ILTV field isolate, 757/11), and two commercially available ILTV CEO vaccine viruses. The wild-type strains were isolated from unvaccinated chicken flocks affected by ILT in 1980, 2007 and 2011. The 1980 and 2007 ILTV strains were isolated from tracheal tissue propagated onto the chorioallantoic membrane (CAM) of SPF embryonated chicken eggs, whereas the 2011 strain was obtained from a tracheal swab. The two ILTV CEO vaccines were those commercialized in Italy as Nobilis Laringovac^®^ (MSD Animal Health S.r.l., Segrate \[MI\], Italy) and Poulvac ILT^®^ (Zoetis Italia S.r.l., Roma, Italy), attenuated by sequential passages in chicken embryos from the Serva and the Salsbury 146 strains, respectively.

Viral DNA Extraction {#sec004}
--------------------

Total viral genomic DNA was extracted directly from the suspension of the inoculated CAMs, the suspension of the tracheal swab and the reconstituted lyophilized vaccines using the High Pure Viral Nucleic Acid Kit (Roche Diagnostics S.p.A, Roche Applied Science, Monza \[MI\], Italy), according to the manufacturer's instructions.

High Throughput Sequencing {#sec005}
--------------------------

Viral genomic DNAs were preliminarily amplified by a conventional PCR in order to enrich the DNA by using the high fidelity Takara LA Taq^™^ DNA Polymerase (Lonza, Basel, Switzerland), allowing the generation of long and accurate PCR products. A set of about 10 kb overlapping amplicons was obtained with the primers summarized in [S1 Table](#pone.0149529.s001){ref-type="supplementary-material"}. Afterward, a shotgun sequencing approach was performed by using the GS Titanium Rapid Library Preparation Kit (Roche). Briefly, amplicons from each viral strain were first pooled equimolarly, and then fragmented by nebulization (at 3 psi for 1 minute), purified, and ligated to adapter-tags with barcodes. DNA fragments were clonally amplified and multiplex sequencing was performed by using the Roche 454 Life Sciences Genome Sequencer FLX platform (Roche 454 Life Sciences, Branford, CT, USA), following the manufacturer's instructions.

Sequencing Data Analysis {#sec006}
------------------------

Images were processed using the runAnalysisPipe command provided with the DataProcessing package (Roche). The resulting sequences were demultiplexed using the SFFtools suite (Roche) and mapped to the ILTV reference sequence (Serva strain, GenBank accession no. HQ630064), using the gsMapper tool provided with the instrument. The same tool was used to detect variants between the ILTV strains sequenced in the study and the reference sequence.

Whole Genome Finishing (Start/End) {#sec007}
----------------------------------

The 5' end of the ILTV genomes was amplified and sequenced with the Sanger method using a pair of primers (Forward: `AATTTCCACCGCGAAATGGC`; Reverse: `AACCGGGGTTTAGAGCTGTG`) designed to obtain a product of 1,292 bp. The 5' and 3' ends of the genomes were also determined following the protocol described by Kong et al. \[[@pone.0149529.ref023]\], consisting of a single oligonucleotide nested PCR (SON-PCR). Briefly, a single primer (`GCGAGGTAGGGAGTGTGGCTGCTG`) was used for the first step of the SON-PCR, whereas the forward primer (`GGTCGGACATGAAACCACAAGG`) mapping at the 3' end and the reverse primer (`TGGGTGCTTGCCTGCATATACC`) mapping at the 5' end of the genome were used for the nested PCR and sequencing.

The five Italian ILTV complete genomes were deposited in the NCBI GenBank database under the accession numbers: KP677881 (4787/80 field isolate), KP677882 (193435/07 field isolate), KP677883 (757/11 field isolate), KP677884 (MSD CEO vaccine) and KP677885 (Zoetis CEO vaccine).

IR/TR Variant Characterization {#sec008}
------------------------------

Since the ILTV internal repeat (IR) and terminal repeat (TR) are almost identical, it was not possible to discriminate the reads from one region to those from the other one. To identify possible differences between the two regions, a modified version of the Serva genome (composed only by UL, IR, and US) was used as reference for mapping. All reads of both IR and TR were assembled and searched for variants with a consensus below 100% of the mapped reads, which could indicate mutations present only in one of the repeat regions, and further analysed with conventional PCR and Sanger sequencing. In particular, two couples of primers able to amplify selectively the IR region, were designed and subsequently targeted to the selected variants with nested PCRs ([S2 Table](#pone.0149529.s002){ref-type="supplementary-material"}). The detection of variants in the IR entailed their absence in the TR and vice versa.

Alignment and Phylogenetic Analysis {#sec009}
-----------------------------------

A multiple alignment including the five ILTV genomes and all the ILTV complete genomes (except for the mosaic sequence of GaHV-1, accession number NC_006623) available in GenBank ([Table 1](#pone.0149529.t001){ref-type="table"}) was built using ClustalW2 \[[@pone.0149529.ref026]\]. Similarly, the translated ORFs of all the genomes were analysed. Phylogenetic trees of selected genes were constructed with Mega 6 \[[@pone.0149529.ref027]\] using the Maximum Likelihood method based on the Tamura-Nei model \[[@pone.0149529.ref028]\].

10.1371/journal.pone.0149529.t001

###### Detailed information of the ILTV complete genomes published in GenBank (accessed 2015 November 5) used in the alignment and phylogenetic analyses.

![](pone.0149529.t001){#pone.0149529.t001g}

  GenBank accession no.                             Definition                            Size (bp)   Virus strain   Vaccine name[^a^](#t001fn001){ref-type="table-fn"}   Country                          Reference   
  ------------------------------------------------- ------------------------------------- ----------- -------------- ---------------------------------------------------- -------------------------------- ----------- ----------------------------------------------
  JX458823                                          GaHV-1 strain WG                      153,505     Virulent       WG                                                   \-                               China       \-
  JX458824                                          GaHV-1 strain K317                    153,639     Virulent       K317                                                 \-                               China       \-
  JX458822                                          GaHV-1 strain LJS09                   153,201     Virulent       LJS09                                                \-                               China       Zhao et al., 2013 \[[@pone.0149529.ref048]\]
  JX646898                                          GaHV-1 strain V1-99                   153,630     Virulent       V1-99                                                \-                               Australia   Lee et al., 2013
  JX646899                                          GaHV-1 strain CSW-1                   151,671     Virulent       CSW-1                                                \-                               Australia   Lee et al., 2013
  JN580317                                          GaHV-1 strain CEO low passage         153,641     Vaccine        Hudson                                               Trachivax, Merck Animal Health   America     García et al., 2013b
  JN580315                                          GaHV-1 strain TCO low passage         155,465     Vaccine        Unknown                                              LT-IVAX, Merck Animal Health     America     García et al., 2013b
  JN580313                                          GaHV-1 strain CEO TRVX                153,647     Vaccine        Hudson                                               Trachivax, Merck Animal Health   America     García et al., 2013b
  JN580316                                          GaHV-1 strain CEO high passage        153,647     Vaccine        Hudson                                               Trachivax, Merck Animal Health   America     García et al., 2013b
  JN580314                                          GaHV-1 strain TCO high passage        150,335     Vaccine        Unknown                                              LT-IVAX, Merck Animal Health     America     García et al., 2013b
  JN580312                                          GaHV-1 strain TCO IVAX                155,465     Vaccine        Unknown                                              LT-IVAX, Merck Animal Health     America     García et al., 2013b
  JN804827                                          GaHV-1 strain CL9                     152,635     Virulent       CL9                                                  \-                               Australia   Lee et al., 2012
  JN804826                                          GaHV-1 strain ACC78                   152,632     Virulent       ACC78                                                \-                               Australia   Lee et al., 2012
  JQ083493                                          GaHV-1 strain vaccine LT Blen         153,623     Vaccine        Cover                                                LT Blen, Merial                  America     Chandra et al., 2012
  JQ083494                                          GaHV-1 strain vaccine Laryngo Vac     153,624     Vaccine        Hudson                                               Laryngo-Vac, Zoetis              America     Chandra et al., 2012
  JN542535                                          GaHV-1 strain 81658                   150,335     Virulent       81658                                                \-                               America     Spatz et al., 2012
  JN542533                                          GaHV-1 strain 1874C5                  149,682     Virulent       1874C5                                               \-                               America     Spatz et al., 2012
  JN542536                                          GaHV-1 strain 63140/C/08/BR           153,633     Virulent       63140/C/08/BR                                        \-                               America     Spatz et al., 2012
  JN542534                                          GaHV-1 strain USDA reference          151,756     Virulent       USDA                                                 \-                               America     Spatz et al., 2012
  JN596963                                          GaHV-1 strain A20                     152,978     Vaccine        A20                                                  Poulvac Laryngo A20, Zoetis      Australia   Lee et al., 2011b
  JN596962                                          GaHV-1 strain SA2                     152,975     Vaccine        SA2                                                  Poulvac Laryngo SA2, Zoetis      Australia   Lee et al., 2011b
  HQ630064                                          GaHV-1 strain live attenuated Serva   152,630     Vaccine        Serva                                                Nobilis ILT, MSD                 Australia   Lee et al., 2011a
  NC_006623[^b^](#t001fn002){ref-type="table-fn"}   Gallid herpesvirus 1                  148,687     \-             \-                                                   \-                               \-          Thureen & Keeler, 2006

^a^ Data obtained from Menendez et al., 2014;

^b^Sequence of ILTV assembled from 14 different published sequences.

This sequence was excluded from the multiple alignment and phylogenetic analyses.

Results and Discussion {#sec010}
======================

Genome Organization {#sec011}
-------------------

High throughput sequencing showed that the size of the five ILTV genomes ranged from 153,650 bp in the two vaccine strains to 153,653 bp in the 4787/80 field isolate and 153,662 bp in the other two field isolates. On average, the G + C content of the genomes was 47.97% and a total of 79 predicted ORFs was identified, according to the Serva reference sequence. A summary of the sequencing results, the full genome and genomic regions (UL, IR, US and TR) lengths and the G + C content of the five strains is shown in [Table 2](#pone.0149529.t002){ref-type="table"}. In [Fig 1](#pone.0149529.g001){ref-type="fig"}, the alignment and the predicted ORFs arrangement of the five genomes with the Serva reference sequence are shown.

![Representation of the nucleotide and amino acid differences detected in the five ILTV genomes.\
The outermost, thick circle is the NCBI ILTV reference sequence (Serva strain, GenBank accession no. HQ630064), where rectangles represent the coding sequences (CDS) and the colour code indicates the transcription strand: cyan refers to CDS in the plus strand, orange stands for minus strand. The inner circles represent the five ILTV genomes sequenced in this study (A = 4787/80, B = 193435/07, C = 757/11, D = MSD CEO vaccine, E = Zoetis CEO vaccine): on each circle, the blue bars indicate silent nucleotide substitutions, while red ones highlight those causing amino acid substitutions. The yellow ribbons in the inner part of the figure connect the coding sequences that are repeated in the ILTV genome. IR: internal repeat; TR: terminal repeat. The plot was obtained with Circos \[[@pone.0149529.ref044]\].](pone.0149529.g001){#pone.0149529.g001}

10.1371/journal.pone.0149529.t002

###### Results of the pyrosequencing run and genomic assembly (NCBI ILTV Serva reference sequence is reported for comparison).

![](pone.0149529.t002){#pone.0149529.t002g}

  Strain                      Number of reads   Average raw read length                        Coverage   Total genome length (bp)   UL (bp)                IR (bp)                     US (bp)                     TR (bp)                     G + C content
  --------------------------- ----------------- ---------------------------------------------- ---------- -------------------------- ---------------------- --------------------------- --------------------------- --------------------------- ---------------
  4787/80 field isolate       44,175            543.27[^a^](#t002fn002){ref-type="table-fn"}   156X       153,653                    112,917 (1--112,917)   13,821 (112,918--126,738)   13,094 (126,739--139,832)   13,821 (139,833--153,653)   48.11%
  193435/07 field isolate     15,657            372.42                                         38X        153,662                    112,926 (1--112,926)   13,821 (112,927--126,747)   13,094 (126,748--139,841)   13,821 (139,842--153,662)   48.1%
  757/11 field isolate        26,867            376.86                                         66X        153,662                    112,926 (1--112,926)   13,821 (112,927--126,747)   13,094 (126,748--139,841)   13,821 (139,842--153,662)   48.1%
  MSD CEO vaccine strain      22,433            377.86                                         55X        153,650                    112,914 (1--112,914)   13,821 (112,915--126,735)   13,094 (126,736--139,829)   13,821 (139,830--153,650)   48.11%
  Zoetis CEO vaccine strain   53,001            385.71                                         133X       153,650                    112,914 (1--112,914)   13,821 (112,915--126,735)   13,094 (126,736--139,829)   13,821 (139,830--153,650)   48.11%
  Serva vaccine strain        \-                \-                                             \-         153,645                    112,915                13,818                      13,094                      13,818                      48%

UL = unique long; IR = internal repeat; US = unique short; TR = terminal repeat; G + C = guanine + cytosine content.

^a^Average read length is considerably higher for the strain 4787/80 because sequencing was conducted on a separate run, after the upgrade of the instrument to FLX Plus.

Significant differences in the ILTV full genome lengths (ranging from 150,335 to 155,465 bp) have been reported \[[@pone.0149529.ref003], [@pone.0149529.ref015], [@pone.0149529.ref016], [@pone.0149529.ref019]--[@pone.0149529.ref023]\], with the extreme values due to large insertions/deletions (INDELs), such as the deletion of about 3.3 kb at the 5' end of the US TCO vaccines and related field strains \[[@pone.0149529.ref016], [@pone.0149529.ref021]\]. Instead, differences in the genome length of the five strains sequenced in this study did not involve large fragments of DNA. Accordingly with Spatz et al. \[[@pone.0149529.ref021]\], a possible error in the assembly of the Serva reference genome was detected: a fragment of 1,016 bp was missing at the 3' end of the TR region leading to an increase in the size of the Serva genome from 152,630 to 153,645 bp. Additionally, the lack of this sequence fragment was identified in the genomes of the Aus CEO vaccines (SA2 and A20), the Aus virulent strains (ACC78 and CL9), and the US 1874C5 field strain.

Overall, the multiple amino acid sequence alignment showed that only 11 ORFs presented different lengths among the ILTV genomes. Compared to the Serva reference sequence, differences in the coding regions of the five strains consisted of an insertion of nine nucleotides (`CCTCCTCTT`, after nt position 1,892; Δ491GluGluGlu) in the UL52 gene of two field strains (193435/07 and 757/11) and an insertion of three nucleotides (ATC, after nt position 813; Δ66Asp) in the ORFC gene of the three field strains. The sequence alignment showed that the insertion of three Glu in the UL52 gene was shared by the two Italian field strains and the Aus V1-99 virulent strain. Notably, this insertion was located in a low complexity region rich of CCT or CTT codons, suggesting a possible replication slippage event. The insertion in ORFC was also present in the US 63140 isolate, a virulent strain closely related to CEO vaccines, in the Aus CEO vaccines (SA2 and A20) and virulent strains (CL9 and CSW-1), and in the Chi WG field strain. Both these mutations in UL52 and ORFC genes should be further investigated in order to clarify their potential impact on viral biology and pathogenesis.

Comparative Analysis {#sec012}
--------------------

Comparative analysis between the five ILTV strains and the Serva reference sequence showed that the nucleotide sequence identity ranged from 99.96% to 99.99%, with the lowest value detected in the 193435/07 and 757/11 field isolates. The DNA sequence identity among the wild-type strains and among the vaccine strains was 99.99% and 99.98%, respectively, whereas that between them ranged from 99.97% to 99.98% ([Table 3](#pone.0149529.t003){ref-type="table"}). All nucleotide and predicted amino acid differences in the coding regions of the five strains compared to the Serva reference sequence are presented in [Table 4](#pone.0149529.t004){ref-type="table"}. Besides the two insertions identified in the UL52 and ORFC genes, nucleotide differences were located in a total of 35 ORFs (including IR and TR variants). The remaining 44 ORFs were completely conserved across the genomes. These findings are consistent with previous studies reporting a pronounced genetic stability in ILTV \[[@pone.0149529.ref003], [@pone.0149529.ref016], [@pone.0149529.ref019]--[@pone.0149529.ref022]\], according to the low mutation rate in members of the *Alphaherpesvirinae* subfamily \[[@pone.0149529.ref029]\]. The multiple amino acid sequence alignment showed that six ORFs were completely conserved among the ILTV genomes. A 100% identity in ORFs of virulent, TCO and CEO vaccine strains from distant geographical areas (*i*.*e*. USA, Australia and China) has been documented previously \[[@pone.0149529.ref016], [@pone.0149529.ref019], [@pone.0149529.ref020]--[@pone.0149529.ref023]\]. The conservation of genes in ILTV strains divergent for geographical origin and virulence suggests that they may not be related to the virulence/attenuation of the virus.

10.1371/journal.pone.0149529.t003

###### Pairwise comparison of the five ILTV strains with the NCBI ILTV reference sequence (Serva strain) (global identity percentage and number of identities over the genome length of the shortest of the two).

![](pone.0149529.t003){#pone.0149529.t003g}

                     MSD CEO                    Zoetis CEO                 193435/07                  757/11                     4787/80                    Serva strain
  ------------------ -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- --------------
  **MSD CEO**        100%                                                                                                                                   
  **Zoetis CEO**     99.98% (153,625/153,650)   100%                                                                                                        
  **193435/07**      99.97% (153,605/153,650)   99.97% (153,610/153,650)   100%                                                                             
  **757/11**         99.97% (153,603/153,650)   99.97% (153,610/153,650)   99.99% (153,660/153,662)   100%                                                  
  **4787/80**        99.97% (153,611/153,650)   99.98% (153,619/153,650)   99.99% (153,638/153,653)   99.99% (153,638/153,653)   100%                       
  **Serva strain**   99.98% (153,609/153,645)   99.97% (153,606/153,645)   99.96% (153,588/153,645)   99.96% (153,586/153,645)   99.97% (153,593/153,645)   100%

10.1371/journal.pone.0149529.t004

###### Summary of nucleotide and amino acid differences in the coding regions of the five ILTV strains *vs* the genome sequence of the NCBI ILTV reference sequence (Serva strain).
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  Gene          CDS                                        Genomic nt position   Nt substitution (strand +)[^a^](#t004fn002){ref-type="table-fn"}   Field strains[^b^](#t004fn003){ref-type="table-fn"}   Vaccine strains[^b^](#t004fn003){ref-type="table-fn"}                                                                                                   
  ------------- ------------------------------------------ --------------------- ------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------- ------------------- -------------------- -------------- ------------------- ------------------- -------------------
  **ORFF**      **Protein IF**                             **437**               **437**                                                            **146**                                               **8,453**                                               **T → C**           **V → A**            \-             \-                  \-                  \-
  **UL54**      **Multifunctional expression regulator**   **199**               **1,437**                                                          **479**                                               **10,844**                                              **T → C**           \-                   \-             \-                  **I → M (60%)**     \-
                                                           **913**               **723**                                                            **241**                                               **11,558**                                              **T → G**           \-                   \-             \-                  \-                  **E → D**
                                                           **1,235**             **401**                                                            **134**                                               **11,880**                                              **C → T**           **S → N**            **S → N**      **S → N**           \-                  \-
  **UL52**      **Helicase-primase primase subunit**       **1,892**             **1,442**                                                          **481**                                               **15,495**                                              **- → CCTCCTCTT**   \-                   **Q → QEEE**   **Q → QEEE**        \-                  \-
  UL50          Deoxyuridine triphosphatase                799                   453                                                                151                                                   18,490                                                  A **→** G           T **→** T            T **→** T      T **→** T           \-                  \-
  UL46          Tegument protein VP11/12                   849                   849                                                                283                                                   22,496                                                  A **→** G           T **→** T            T **→** T      T **→** T           \-                  \-
  ORFA          Protein IA                                 360                   360                                                                120                                                   25,397                                                  A **→** C           S **→** S            S **→** S      S **→** S (90.9%)   \-                  \-
                                                           465                   465                                                                155                                                   25,502                                                  C **→** T           \-                   V **→** V      V **→** V (94.6%)   \-                  \-
  ORFB          Protein IB                                 352                   352                                                                118                                                   26,559                                                  A **→** C           R **→** R            R **→** R      R **→** R           \-                  \-
                                                           744                   744                                                                248                                                   26,951                                                  T **→** C           \-                   \-             A **→** A           \-                  \-
  **ORFC**      **Protein IC**                             **813**               **197**                                                            **66**                                                **28,097**                                              **- → ATC**         **D → DD (90.3%)**   **D → DD**     **D → DD**          \-                  \-
  **ORFE**      **Protein IE**                             **836**               **398**                                                            **133**                                               **30,430**                                              **C → G**           **G → A**            **G → A**      **G → A**           \-                  \-
                                                           1042                  192                                                                64                                                    30,636                                                  C **→** T           \-                   S **→** S      S **→** S           \-                  \-
  UL23          Thymidine kinase                           553                   540                                                                180                                                   33,885                                                  G **→** A           D → D                D → D          D → D               \-                  \-
  **UL27**      **Envelope glycoprotein B**                **722**               **1931**                                                           **644**                                               **39,573**                                              **A → G**           **I → T**            **I → T**      **I → T**           \-                  \-
                                                           **2306**              **347**                                                            **116**                                               **41,157**                                              **A → G**           **V → A**            **V → A**      **V → A**           \-                  **V → A (95.1%)**
  **UL28**      **DNA packaging terminase subunit 2**      **383**               **1913**                                                           **638**                                               **41,857**                                              **A → G**           **V → A**            **V → A**      **V → A**           **V → A (66.7%)**   **V → A**
  **UL36**      **Large tegument protein**                 **413**               **7943**                                                           **2648**                                              **55,613**                                              **C → T**           \-                   \-             \-                  **R → H (33.3%)**   \-
                                                           679                   7677                                                               2559                                                  55,879                                                  T → C               T → T (98.3%)        T → T          T → T               \-                  \-
                                                           2386                  5970                                                               1990                                                  57,586                                                  C → T               \-                   G → G          G → G               \-                  \-
                                                           **4316**              **4040**                                                           **1347**                                              **59,516**                                              **C → T**           **R → H**            **R → H**      **R → H**           \-                  \-
                                                           **7532**              **824**                                                            **275**                                               **62,732**                                              **G → A**           \-                   \-             \-                  \-                  **A → V (65.2%)**
  UL41          Tegument host shutoff protein              832                   369                                                                123                                                   72,697                                                  A → G               \-                   \-             \-                  R → R (10.3%)       \-
  **UL43**      **Envelope protein UL43**                  369                   369                                                                123                                                   75,044                                                  T **→** C           \-                   \-             \-                  F → F               \-
                                                           **761**               **761**                                                            **254**                                               **75,436**                                              **C → T**           \-                   \-             \-                  **T → I (36.8%)**   \-
  UL44          Envelope glycoprotein C                    180                   180                                                                60                                                    76,749                                                  A → G               \-                   \-             E → E (10.3%)       \-                  \-
  **UL21**      **Tegument protein UL21**                  **211**               **1389**                                                           **463**                                               **78,110**                                              **C → A**           \-                   **K → N**      **K → N**           \-                  \-
  UL19          Major capsid protein                       3870                  3870                                                               1291                                                  84,421                                                  C → T               \-                   L → L          L → L               \-                  \-
  UL14          Tegument protein UL14                      459                   459                                                                153                                                   90,940                                                  A → G               \-                   \-             \-                  \-                  L → L
  **UL10**      **Envelope glycoprotein M**                **1059**              **124**                                                            **42**                                                **95,522**                                              **T → C**           **T → A**            **T → A**      **T → A**           \-                  **T → A (56%)**
  UL9           DNA replication origin-binding helicase    78                    78                                                                 26                                                    95,671                                                  T → C               \-                   \-             \-                  \-                  P → P
  **UL5**       **Helicase-primase helicase subunit**      **1027**              **1027**                                                           **343**                                               **104,708**                                             **A → G**           **K → E**            **K → E**      **K → E**           \-                  \-
  **UL1**       **Envelope glycoprotein L**                **287**               **161**                                                            **54**                                                **109,069**                                             **T → G**           **Q → P**            **Q → P**      **Q → P**           **Q → P**           **Q → P**
  **ICP4**      **Transcriptional regulator ICP4**         169                   4281                                                               1427                                                  115,469                                                 C → T               G → G                G → G          G → G               G → G               G → G
                                                           **2108**              **2342**                                                           **781**                                               **117,408**                                             **T → C**           **H → R**            **H → R**      **H → R**           **H → R**           **H → R**
                                                           3460                  990                                                                330                                                   118,760                                                 T → C               \-                   \-             \-                  \-                  S → S
                                                           3778                  672                                                                224                                                   119,078                                                 T → C               \-                   \-             \-                  \-                  E → E
  **sORF4/3**   **Protein sORF4/3**                        **444**               **442**                                                            **148**                                               **126,167**                                             **C → T**           **A → T**            **A → T**      **A → T**           \-                  \-
                                                           **452**               **434**                                                            **145**                                               **126,175**                                             **C → A**           \-                   **R → L**      **R → L**           \-                  \-
  US2           Virion protein US2                         289                   402                                                                134                                                   127,028                                                 G → A               \-                   F → F          F → F               \-                  \-
  US3           Serine/threonine protein kinase US3        1200                  1200                                                               400                                                   128,717                                                 A → G               G → G                G → G          G → G               \-                  \-
  UL47          Tegument protein VP13/14                   1812                  1812                                                               604                                                   130,845                                                 A → G               \-                   \-             \-                  S → S (47.6%)       \-
  US4           Envelope glycoprotein G                    33                    33                                                                 11                                                    131,101                                                 C → T               \-                   \-             A → A (16%)         \-                  \-
                                                           765                   765                                                                255                                                   131,833                                                 G → A               \-                   E → E          \-                  \-                  \-
  **US5**       **Envelope glycoprotein J**                777                   777                                                                259                                                   132,933                                                 T → C               \-                   \-             \-                  I → I (31.6%)       \-
                                                           **2345**              **2345**                                                           **782**                                               **134,501**                                             **A → G**           **D → G (10%)**      \-             \-                  \-                  \-
  **US6**       **Envelope glycoprotein D**                **401**               **401**                                                            **134**                                               **135,322**                                             **C → T**           \-                   **S → L**      **S → L**           \-                  \-
  **US8**       **Envelope glycoprotein E**                **629**               **629**                                                            **210**                                               **138,244**                                             **A → G**           **K → R**            **K → R**      **K → R**           \-                  **K → R**
  **sORF4/3**   **Protein sORF4/3**                        **307**               **307**                                                            **103**                                               **140,259**                                             **C-\>T**           \-                   \-                                 \-                  **P → S (10.7%)**
                                                           **434**               **434**                                                            **145**                                               **140,386**                                             **G-\>T**           \-                   **R → L**      **R → L**           \-                  \-
                                                           **442**               **442**                                                            **148**                                               **140,394**                                             **G-\>A**           **A → T**            **A → T**      **A → T**           \-                  \-
  **US10**      **Virion protein US10**                    **489**               **349**                                                            **117**                                               **141,692**                                             **C-\>T**           \-                   \-             \-                  \-                  **A → T (35.3%)**
  **ICP4**      **Transcriptional regulator ICP4**         672                   672                                                                224                                                   147,483                                                 A-\>G               \-                   \-             \-                  \-                  E → E
                                                           **2342**              **2342**                                                           **781**                                               **149,153**                                             **A-\>G**           **H → R**            \-             **H → R**           \-                  **H → R**
                                                           4281                  4281                                                               1427                                                  151,092                                                 G-\>A               G → G                G → G          G → G               \-                  G → G

CDS = coding DNA sequence; Nt = nucleotide; AA = amino acid.

^a^Nucleotide in the reference sequence (Serva strain);

^b^Predicted AA; Percentages indicate the amount of reads bearing the variant (not reported when 100%).

In bold non-synonymous nt substitutions.

Comparing the three field isolates with the Serva reference sequence, a total of 38 SNPs and two insertions were identified ([Table 4](#pone.0149529.t004){ref-type="table"}). Eighteen SNPs were synonymous and 20 non-synonymous. Thirteen non-synonymous SNPs were found in all the three wild-type strains. Non-synonymous SNPs in ORFF (T437C; Val146Ala) and US5 (A777G; Asp259Gly) were detected only in the 4787/80 isolate; SNPs in UL21 (C1389A; Lys463Asp), sORF4/3-IR/TR (C434A; Arg145Leu and G434T, Arg145Leu, respectively), and US6 (C401T; Ser134Leu) only in the 193435/07 and 757/11 isolates; and SNP in ICP4-TR (A2342G; His781Arg) only in the 4787/80 and 757/11 isolates. The comparison between the two vaccine strains and the Serva reference sequence revealed a total of 25 SNPs ([Table 4](#pone.0149529.t004){ref-type="table"}). Eleven SNPs were synonymous and 14 non-synonymous. Three non-synonymous SNPs were detected in both the vaccine strains, as well as in the three wild-type isolates. Three SNPs were unique to the MSD CEO vaccine strain, while eight were detected only in the Zoetis CEO vaccine. SNPs in UL27, UL10, and US8 were also present in the three wild-type strains, whereas the nucleotide substitution in ICP4-TR was present only in two (4787/80 and 757/11) of the three field isolates. Notably, some non-synonymous SNPs were present only in a portion of reads supporting the hypothesis of the existence of viral subpopulations \[[@pone.0149529.ref016], [@pone.0149529.ref022]\]. Nucleotide and amino acid differences were also identified between the two repeat regions (IR and TR) of the five strains ([Table 4](#pone.0149529.t004){ref-type="table"}). To our knowledge, no other studies have reported any difference between the IR and TR of ILTV genome.

In [Table 5](#pone.0149529.t005){ref-type="table"}, amino acid differences in the coding regions of the five strains compared to the complete ILTV genomes available in GenBank are summarized. Among 12 ILTV genes encoding for surface glycoproteins \[[@pone.0149529.ref001]\], six (*i*.*e*. UL27, UL10, UL1, US5, US6, and US8 encoding for gB, gM, gL, gJ, gD, and gE, respectively) revealed at least one amino acid change, and many of these mutations were also present in other ILTV strains. Spatz et al. \[[@pone.0149529.ref021]\] suggested that mutations in the surface glycoproteins gB, gM, gE and gL might have been caused by the different geographical origin of the European Serva strain and the US virulent strains. Interestingly, we found these mutations either in European ILTV field and CEO vaccine strains, including the historical 4787/80 isolate. Therefore, mutations in the surface glycoproteins may not only have been caused by the geographical pressure, but they may also be related to virulence/attenuation of ILTV, given the important role these proteins play in host range and pathogenicity \[[@pone.0149529.ref030]\]. Besides the mutation Gln54Pro in the UL1 gene present in all the ILTV strains (except for the Serva strain and the Chi WG and K317 strains), most of the mutations (*i*.*e*. UL27 Val116Ala, UL10 Thr42Ala, and US8 Lys210Arg) were identified either in virulent and attenuated CEO and TCO vaccine strains. Therefore, they do not seem to be useful for discriminating between wild-type and vaccine ILTV strains. On the other hand, the mutation Ile644Thr in the UL27 gene was shared by all the virulent strains (except for the Chi LJS09 and K317) and lacking in all the vaccine strains (except for the Aus SA2 and A20), as previously documented by García et al. \[[@pone.0149529.ref016]\]. This mutation indeed appears to be a good marker for discriminating between field and vaccine strains. It should be mentioned that glycoprotein B (encoded by the UL27 gene) plays a fundamental role in herpesvirus attachment to target cells and cell entry \[[@pone.0149529.ref031]\]; then it could affect viral tropism and infectivity. The mutations found in the US5 and US6 genes were exclusive of the strains sequenced in this study and not reported previously. Notably, the mutation in the US6 gene was shared only by the two recent field isolates (193435/07 and 757/11). This gene encodes for the surface glycoprotein D that functions as receptor for herpesvirus and ILTV binding and entry to susceptible cells \[[@pone.0149529.ref032], [@pone.0149529.ref033]\]. Additionally, this protein acts synergistically with the glycoprotein J (encoded by the US5 gene), which plays a key role in herpesvirus infection by blocking the apoptotic cascade \[[@pone.0149529.ref034]\], affecting the virus ability to infect productively target cells.

10.1371/journal.pone.0149529.t005

###### Summary of the amino acid differences in coding regions of the five ILTV strains *vs* other ILTV complete genomes published in GenBank (accessed 2015 November 5).

![](pone.0149529.t005){#pone.0149529.t005g}

  Gene          AA position   4787/80 virulent   193435/07 virulent   757/11 virulent   MSD CEO vaccine   Zoetis CEO vaccine   Serva CEO vaccine   SA2 CEO vaccine   A20 CEO/TCO vaccine   USDA virulent   63140 virulent   1874C5 virulent   81658 virulent   ACC78 virulent   CL9 virulent   LT-Blen CEO vaccine   Laryngo-Vac CEO vaccine   Trachivax CEO vaccine   LT-IVAX TCO vaccine   V1-99 virulent   CSW-1 virulent   LJS09 virulent   WG virulent   K317 virulent
  ------------- ------------- ------------------ -------------------- ----------------- ----------------- -------------------- ------------------- ----------------- --------------------- --------------- ---------------- ----------------- ---------------- ---------------- -------------- --------------------- ------------------------- ----------------------- --------------------- ---------------- ---------------- ---------------- ------------- ---------------
  **ORFF**      146           A                  V                    V                 V                 V                    V                   V                 V                     V               V                V                 V                V                V              V                     V                         V                       V                     V                V                V                V             V
  **UL54**      479           I                  I                    I                 M                 I                    I                   I                 I                     I               I                I                 I                I                M              M                     I                         M                       I                     I                I                M                M             I
                241           E                  E                    E                 E                 D                    E                   E                 E                     E               E                E                 E                E                E              E                     D                         E                       E                     E                E                E                E             E
                134           N                  N                    N                 S                 S                    S                   S                 S                     S               S                S                 S                S                S              S                     S                         S                       S                     S                S                S                S             S
  **UL52**      491           Q                  QEEE                 QEEE              Q                 Q                    Q                   Q                 Q                     Q               Q                Q                 Q                Q                Q              Q                     Q                         Q                       Q                     QEEE             Q                Q                Q             Q
  **ORFC**      66            DD                 DD                   DD                D                 D                    D                   DD                DD                    D               DD               D                 D                D                DD             D                     D                         D                       D                     D                DD               D                DD            D
  **ORFE**      133           A                  A                    A                 G                 G                    G                   G                 G                     G               A                G                 G                G                G              G                     G                         G                       G                     G                G                G                G             G
  **UL27**      644           T                  T                    T                 I                 I                    I                   T                 T                     T               T                T                 I                T                T              I                     I                         I                       I                     T                T                I                T             I
                116           A                  A                    A                 V                 A                    V                   A                 A                     A               A                A                 A                A                A              A                     A                         A                       A                     A                A                V                A             A
  **UL28**      638           A                  A                    A                 A                 A                    V                   A                 A                     A               A                A                 A                A                A              A                     A                         A                       A                     A                V                V                A             A
  **UL36**      2648          R                  R                    R                 H (33.3%)         R                    R                   R                 R                     R               R                R                 R                R                R              R                     R                         R                       R                     R                R                H                R             R
                1347          H                  H                    H                 R                 R                    R                   H                 H                     R               H                H                 R                R                H              R                     R                         R                       R                     H                H                R                H             R
                275           A                  A                    A                 A                 V                    A                   A                 A                     A               A                A                 A                A                A              A                     V                         A                       A                     A                A                A                A             A
  **UL43**      254           T                  T                    T                 I (36.8%)         T                    T                   T                 T                     T               T                T                 T                T                T              T                     T                         T                       T                     T                T                I                T             T
  **UL21**      463           K                  N                    N                 K                 K                    K                   K                 K                     K               K                K                 K                K                K              K                     K                         K                       K                     K                K                K                K             K
  **UL10**      42            A                  A                    A                 T                 A                    T                   A                 A                     A               A                A                 A                T                A              T                     T                         T                       A                     A                A                T                T             T
  **UL5**       343           E                  E                    E                 K                 K                    K                   E                 E                     E               E                E                 E                K                E              K                     K                         K                       E                     E                E                K                E             K
  **UL1**       54            P                  P                    P                 P                 P                    Q                   P                 P                     P               P                P                 P                P                P              P                     P                         P                       P                     P                P                P                Q             Q
  **ICP4**      781           R                  R                    R                 R                 R                    H                   R                 R                     R               R                R                 R                H                H              R                     R                         R                       R                     R                R                H                R             R
  **sORF4/3**   148           T                  T                    T                 A                 A                    A                   A                 A                     A               A                A                 A                A                A              A                     A                         A                       A                     A                A                A                A             A
                145           R                  L                    L                 R                 R                    R                   R                 R                     R               R                R                 R                R                R              R                     R                         R                       R                     R                R                R                R             R
  **US5**       782           G (10%)            D                    D                 D                 D                    D                   D                 D                     D               D                D                 D                D                D              D                     D                         D                       D                     D                D                D                D             D
  **US6**       134           S                  L                    L                 S                 S                    S                   S                 S                     S               S                S                 S                S                S              S                     S                         S                       S                     S                S                S                S             S
  **US8**       210           R                  R                    R                 K                 R                    K                   R                 R                     R               R                R                 R                K                K              K                     R                         K                       R                     R                R                K                R             K
  **sORF4/3**   103           P                  P                    P                 P                 S (10.7%)            P                   P                 P                     P               P                P                 P                P                P              P                     P                         P                       P                     P                P                P                P             P
                145           R                  L                    L                 R                 R                    R                   R                 R                     R               R                R                 R                R                R              R                     R                         R                       R                     R                R                R                R             R
                148           T                  T                    T                 A                 A                    A                   A                 A                     A               A                A                 A                A                A              A                     A                         A                       A                     A                A                A                A             A
  **US10**      117           A                  A                    A                 A                 T                    A                   A                 A                     A               A                A                 A                A                A              A                     T                         A                       A                     A                A                A                A             A
  **ICP4**      781           R                  H                    R                 H                 R                    H                   R                 R                     R               R                R                 R                H                H              R                     R                         R                       R                     R                R                H                R             R

AA = amino acid; Percentages indicate the amount of reads bearing the variant (not reported when 100%). Strains and GenBank accession numbers: Serva (HQ630064), SA2 (JN596962), A20 (JN596963), USDA (JN542534), 63140 (JN542536), 1874C5 (JN542533), 81658 (JN542535), ACC78 (JN804826), CL9 (JN804827), LT-Blen (JQ083494), Laryngo-Vac (JQ083493), Trachivax (JN580312), LT-IVAX (JN580313), V1-99 (JX646898), CSW-1 (646899), LJS09 (JX458822), WG (JX458823), and K317 (JX458824).

Non-synonymous SNPs were found among genes encoding for viral enzymes, which play a fundamental role during the replication cycle of herpesviruses by mediating the synthesis of viral DNA \[[@pone.0149529.ref035]\]. Mutations were found in the UL28 gene encoding for the DNA packaging terminase subunit 2, and the UL5 gene encoding for the helicase-primase helicase subunit. The mutation in the UL5 gene was found mainly in field strains, appearing to be discriminating between wild-type and vaccine strains, whereas that in the UL28 gene was found in most of the ILTV strains including field, CEO and TCO vaccine strains. Additionally, an insertion in the UL52 gene was uniquely identified in the two recent field isolates (193435/07 and 757/11) and in the Aus V1-99 virulent strain. Together with the UL5 and UL8 genes, the UL52 gene encodes for a component of the helicase-primase complex, which is essential for DNA replication fidelity of herpesviruses and thus for virus propagation \[[@pone.0149529.ref036]\]. Therefore, the biological significance of such mutation requires further investigation in order to determine if it may be involved in the genome stability and in the modulation of the virulence of the recent Italian ILTV field strains.

Among genes encoding for ILTV transcriptional regulatory proteins, ICP4 and UL54 showed amino acid differences. In the ICP4 gene, only a single amino acid change was identified in the five genomes, and it was shared by most of the strains including field, CEO and TCO vaccine strains. Among the three amino acid changes identified in the UL54 gene, the Ile479Met was present only in the MSD CEO vaccine and the Glu241Asp only in the Zoetis CEO vaccine. Similarly, Chandra et al. \[[@pone.0149529.ref022]\] found the same mutations in the LT-Blen and Laryngo-Vac CEO vaccines and García et al. \[[@pone.0149529.ref016]\] in the Trachivax CEO vaccine. Interestingly, the third mutation (Ser134Asn) was exclusive of the three field isolates sequenced in this study. The UL54 gene encodes for the infected cell protein 27, a multifunctional regulatory protein functioning in all stages of mRNA biogenesis from transcription, RNA processing and export through translation \[[@pone.0149529.ref037]\]. Therefore, the Ser134Asn mutation could have an impact on the efficiency of the viral replication cycle. In addition, it seems to be useful for discriminating between the Italian field and vaccine strains.

Amino acid changes were also found in genes encoding for structural proteins, such as the viral tegument proteins UL36 (large tegument protein) and UL21 (tegument protein UL21), and encoding for the viral capsid protein UL43 (envelope protein UL43). Among all the mutations detected in the UL36 gene, only the Arg1347His has been already described in the US 63140 field strain \[[@pone.0149529.ref016]\]. The UL36 gene encodes for the largest tegument protein of ILTV, which has been demonstrated essential for virion assembly in herpesviruses, particularly for the formation of structurally normal connections to the capsid in the initial stages of tegument addition \[[@pone.0149529.ref038]\]. In this study, the mutation was identified in all the three ILTV field strains and in other wild-type ILTV strains, appearing discriminating between field and vaccine strains. As for the UL54 gene, the Ala275Val mutation was identified only in the Zoetis CEO vaccine sequenced in this study and in the US Laryngo-Vac CEO vaccine sequenced by Chandra et al. \[[@pone.0149529.ref022]\]. The mutation in the UL21 gene was exclusive of the two recent field strains (193435/07 and 757/11) and not reported previously. The UL21 gene encodes for a conserved protein of the alphaherpesvirus tegument, essential for virus propagation and expressed during the early and late stages of the replication cycle \[[@pone.0149529.ref039]\]. Tegument addition in herpesvirus morphogenesis is a complex event involving several proteins. In addition, proteins of the tegument can have regulatory or enzymatic activities. Mutations on these proteins can affect the efficiency of viral assembly and the ability to produce an infective viral progeny \[[@pone.0149529.ref038], [@pone.0149529.ref039]\]. The mutation in the UL43 gene was found exclusively in the MSD CEO vaccine and the Chi LJS09 field strain.

A number of non-synonymous SNPs and an insertion was found in the ORFF, ORFC, ORFE, sORF4/3 and US10 genes, whose function is still unknown \[[@pone.0149529.ref001]\]. The ORFC and ORFE genes are known to be unique genes of the members of the *Iltovirus* genus \[[@pone.0149529.ref030]\] and previous studies carried out by Veits et al. \[[@pone.0149529.ref040]\] demonstrated that they are expressed during infection, but not essential for ILTV replication. As for the insertion in the ORFC gene of the three field strains, in the ORFE gene a mutation exclusive of these strains and the US 63140 isolate was found. Our finding is in agreement with Spatz et al. \[[@pone.0149529.ref021]\] and García et al. \[[@pone.0149529.ref016]\], who suggested that it may discriminate between the US 63140 CEO-related field strain and the US CEO vaccine strains and be involved in ILTV attenuation/virulence. In the ORFF gene, a single mutation was found only in the 4787/80 strain and not in the other strains. Similarly to other genes (*i*.*e*. UL54 and UL36), the mutation in the US10 gene was found only in the Zoetis CEO vaccine sequenced in this study and in the US Laryngo-Vac CEO vaccine. The two mutations in the sORF4/3 gene were present only in the Italian field strains: the Arg145Leu in all the three field isolates, the Ala148Thr only in the two recent isolates (193435/07 and 757/11).

Although several mutations were identified only in field strains, allowing the possibility to discriminate between field and vaccine strains in epidemiological studies, it is needed to clarify their physiological function and their potential impact on ILTV biology to identify the genetic determinants of ILT pathogenesis. In particular, it is essential the characterization of the function of the unique genes of the *Iltovirus* genus members that could play a key role on the modulation of the virulence.

Interestingly, the two Italian CEO vaccines (MSD and Zoetis) were more closely related to the US CEO vaccines than to the European Serva strain. In particular, the MSD CEO vaccine was almost identical to the US LT-Blen and Trachivax CEO vaccines, and the Zoetis CEO vaccine to the US Laryngo-Vac CEO vaccine. This finding needs to be further investigated since the Italian MSD CEO vaccine is reported to contain the Serva strain and the Italian Zoetis CEO vaccine the Salsbury strain, whereas the US CEO vaccines are reported to contain the Hudson strain (LT-Blen, Merial Select and Trachivax, Merck Animal Health) and the Cover strain (Laryngo-Vac, Fort-Dodge Animal Health) \[[@pone.0149529.ref003], [@pone.0149529.ref016], [@pone.0149529.ref022]\].

Although a very high sequence identity among the five ILTV strains was detected, the most relevant finding of this study was the pronounced genetic similarity (99.99%) between the historical field strain and the two recent field isolates (193435/07 and 757/11). The 4787/80 strain was isolated during a severe ILT outbreak occurred in the '80s when the vaccination against ILT had not yet been introduced in Italy \[[@pone.0149529.ref024]\]. The other two strains were instead isolated from outbreaks of ILT occurred recently (2007 and 2011, respectively) in unvaccinated broiler flocks, showing mild clinical signs of the disease \[[@pone.0149529.ref025]\]. In a previous study \[[@pone.0149529.ref025]\], the Authors postulated that the recent Italian ILT outbreaks were caused by strains closely related to CEO vaccines based on the results of a multi-loci PCR-RFLP and sequencing of a number of field isolates and CEO vaccines. Interestingly, analysis of partial sequences discriminated between them. Most of the studies aimed at differentiating ILTV wild-type and vaccine strains have been based on single- or multi-locus PCR-RFLP \[[@pone.0149529.ref010], [@pone.0149529.ref012], [@pone.0149529.ref013], [@pone.0149529.ref017], [@pone.0149529.ref041], [@pone.0149529.ref042]\] and sequencing \[[@pone.0149529.ref011]\] or both \[[@pone.0149529.ref007]--[@pone.0149529.ref009]\]. More recently, full genome sequencing has been used to genotype ILTV, but these studies are still very few \[[@pone.0149529.ref003], [@pone.0149529.ref015], [@pone.0149529.ref016], [@pone.0149529.ref019]--[@pone.0149529.ref023]\]. The genetic variation across the full genome sequences indicated that the field strains were either closely related to CEO vaccines and highly correlated each other, even though they derived from two distinct epidemics of ILT occurred in a period spanning almost 30 years and with different ILT control programs implemented by the Italian poultry industry. Therefore, we recommend that ILTV strain identification should be based on full genome analysis.

Phylogenetic Analysis {#sec013}
---------------------

Some of the genes with the highest variability among the ILTV complete genomes were selected to perform phylogenetic analyses. According to Lee et al. \[[@pone.0149529.ref020]\] and to our data, we chose the UL27, UL36, ICP4, and sORF4/3 genes: their nucleotide sequences, obtained from all the complete ILTV genomes available in GenBank, were analysed with the Maximum Likelihood method and the resulting trees are reported in [Fig 2](#pone.0149529.g002){ref-type="fig"}. In all cases, the Australian vaccine strains SA2 and A20 clustered separately from the US and European genomes, with the only exception represented by the virulent strain 1874C5 in the ICP4-related tree ([Fig 2C](#pone.0149529.g002){ref-type="fig"}). On the other hand, the US and European CEO vaccines were always contained in a common cluster, which included also other virulent ILTV strains from China (LJS09 and K317), Australia (ACC78), and USA (63140). Also García et al. \[[@pone.0149529.ref016]\] and Menendez et al. \[[@pone.0149529.ref006]\] recognized a distinct phylogenetic group including CEO vaccines and the US 63140 strain, suggesting that this strain was a revertant of CEO vaccines. As regards the genomes sequenced in this study, the Zoetis and MSD vaccines clustered always with the other CEO vaccines, with the MSD showing a closer relationship to the Serva strain, while the three field isolates 4787/80, 193435/07 and 757/11 grouped together ([Fig 2B and 2D](#pone.0149529.g002){ref-type="fig"}), even though separated by a quite long spanning time. Overall, this phylogenetic analysis suggests that the Italian field strains may be closely related to CEO vaccines, even if the 4787/80 strain was isolated before the introduction of ILT vaccination in Italy.

![Evolutionary relationships of taxa.\
The evolutionary history was inferred using the Maximum Likelihood method based on the Tamura-Nei model \[[@pone.0149529.ref028]\] on four different genes: UL27 (A), UL36 (B), ICP4 (C), and sORF4/3 (D). ILTV genomes sequenced in this study are highlighted in red (field strains) and green (vaccine strains). The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches \[[@pone.0149529.ref045]\]. All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA6 \[[@pone.0149529.ref027]\].](pone.0149529.g002){#pone.0149529.g002}

In the last decade, molecular epidemiological studies have provided evidence that ILTV strains identical or closely related to CEO (and to a lesser extent to TCO) vaccines in America, Asia, Australia, and Europe \[[@pone.0149529.ref007]--[@pone.0149529.ref018]\] and ILTV strains originated by natural recombination of CEO vaccines (*i*.*e*. Serva and SA2/A20 vaccine strains) in Australia \[[@pone.0149529.ref015], [@pone.0149529.ref020]\] have been the cause of ILT outbreaks, even in regions of the world where live attenuated vaccines were not used \[[@pone.0149529.ref009], [@pone.0149529.ref011], [@pone.0149529.ref012], [@pone.0149529.ref043]\].

In order to obtain a global representation of the relationships existing among the currently known ILTV genomes, including the presence of recombinants, we generated a split network with 18 full genomes ([Fig 3](#pone.0149529.g003){ref-type="fig"}). The network confirms the close relationship between the Italian field strains and the CEO vaccines; nevertheless, the Italian isolates grouped together in a single cluster, and a further split included also the US 63140 field strain. This result, together with the high sequence similarity existing between the historical Italian strain and the CEO vaccines, suggests that an already existing CEO revertant ILTV strain could have been present in Italy at that time and be the cause of the epidemic of the '80s. A recent study of Lee et al. \[[@pone.0149529.ref020]\] demonstrated that the Australian CEO vaccine SA2 was very similar to ILTV strains isolated from backyard flocks in the US, suggesting that this strain shared a common ancestor originated in the American continent and subsequently introduced into Australia. Therefore, it is reasonable to suppose that the precursor of the Italian ILTV wild-type strain might have been a CEO revertant, perhaps introduced into Italy from the US.

![Split network showing reticulate evolutionary events of ILTV genomes.\
The network was obtained from the nucleotide sequences of Unique Long, Internal Repeat and Unique Short regions of ILTV genome using SplitsTree4 \[[@pone.0149529.ref046]\] based on the neighbor-net method \[[@pone.0149529.ref047]\]. The Italian field strains (in red) and the vaccine strains (in green) are closely related to the American CEO vaccines; in the zoomed inset, the split separating the field strains from all the other genomes is highlighted in red, while the one grouping them to the American virulent strain 63140 is in blue.](pone.0149529.g003){#pone.0149529.g003}

Conclusions {#sec014}
===========

This is the first study reporting the full genomic sequences of Italian ILTV field and vaccine strains and providing valuable data about genomic variation of divergent ILTV strains from a new geographical region, such as Europe. Several mutations were identified across the genomes: some previously reported as associated with ILTV pathogenicity, some novel and exclusive of the Italian strains. The comparison of the genomes of wild-type strains isolated during epidemics occurred across a quite long spanning time suggested that Italian ILT outbreaks might have been related to a CEO revertant ILTV strain, maybe generated in the past. Further studies are required to better define the molecular determinants associated with ILTV virulence/attenuation and to individuate definitive markers associated with the virulence phenotypes, as well as to clarify the molecular epidemiology of ILT, recently challenged by the circulation of strains originated from live attenuated vaccines, and to identify the origin of strains circulating in poultry flocks.

Supporting Information {#sec015}
======================

###### Primers designed for preliminary PCR of the five ILTV genomes.

Nt = nucleotide; Primers were designed on the NCBI ILTV reference sequence (Gallid Herpesvirus 1, GenBank accession no. NC_006623).

(DOC)

###### 

Click here for additional data file.

###### Primers designed for PCR and sequencing of the IR and for nested PCR and sequencing of the IR/TR variants of the five ILTV strains.

(DOC)

###### 

Click here for additional data file.
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